重篤な臍出血により診断された新規のp.G435Sと既知のp.G244R変異をもつ複合ヘテロ接合体の先天性X因子欠乏症の解析 by 松尾 陽子
INTRODUCTION
Coagulation factor X (FX) is a vitamin 
K-dependent protein that is produced by hepatocytes, 
circulates as a precursor of the serine protease, factor 
Xa, and is activated by F IXa and cofactor VIIIa, and/
or by F VIIa + tissue factor on cell surface membrane 
phospholipids in the presence of Ca2+. FXa converts 
prothrombin to thrombin with the assistance of F Va 
and Ca2+ on a suitable negatively charged phospholipid 
membrane, and exerts an important physiological role 
on hemostasis [1]. Mature FX is physiologically sepa-
rated into a γ-carboxyglutamic acid (Gla) domain, epi-
dermal growth factor domain, activation peptide, and 
catalytic domain [2].
The gene coding FX (F10) is located at chromo-
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Summary:  A 10-day-old male patient was referred to our hospital with severe umbilical bleeding. 
Prothrombin time (PT) and activated partial thromboplastin time (APTT) were prominently prolonged. Plasma 
coagulation factor X (FX) activity and antigen levels were 1% and 0.6%, respectively. A DNA sequence analysis 
of his leukocytes revealed a compound heterozygous state; known Gly244 to Arg (p.G244R) in exon 6 and a 
novel mutation of Gly 435 to Ser (p.G435S) in exon 8. A pedigree analysis showed that p.G244R originated from 
the paternal side, while p.G435S was from the maternal side. A p.G244R mutation was reported previously as 
FXDebrecen and this mutated protein was synthesized as a non-secretable protein.
The glycine at amino acid position 435 in the C-terminal region is completely conserved in the trypsin-like 
serine protease family, including thrombin, FVII, protein C, plasmin, trypsin, and chymotrypsin. In a three-
dimensional structural model of FX, Gly 435 was located within the 11th β-strand and buried in the back of the 
catalytic pocket. Therefore, the substitution to serine was expected to disrupt this structure. p.G435S FX was 
also predicted to be synthesized and exist in the cytoplasm, but not to be secreted into culture media by a cDNA 
expression assay. These two mutations may be responsible for the type 1 (null levels of both activity and antigen 
in plasma) FX deficiency with severe bleeding phenotype.
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some 13q34 and spans 27 kb. F10 has been shown to 
contain 8 coding exons that correspond to 488 amino 
acids [3-4].
Congenital FX deficiency shows autosomal reces-
sive inheritance with an incidence of one in 500,000 
individuals. More than 100 mutations have been iden-
tified in the F10 gene, the majority of which are mis-
sense mutations [5-7].
Patients with FX deficiency exhibit various bleed-
ing tendencies. Previous studies conducted in Japan re-
ported that most patients were aged 10 years or older 
and presented with subcutaneous hemorrhage, epistax-
is, menorrhagia, gastrointestinal bleeding, and bleed-
ing after surgery or trauma. However, the severity of 
FX deficiency varies from mild to serious, and depends 
on the degree of residual plasma FX activity [8-10].
We herein present a case of congenital FX deficien-
cy that presented with massive hemorrhage from the 
umbilical stump, and a genetic analysis revealed com-
pound heterozygosity with the missense mutations of 
novel p.G435S and known p.G244R.
CASE REPORT
History of present illness
No significant events were reported during the peri-
natal period or delivery. The patient was born by vagi-
nal delivery at 40 weeks and 4 days gestation with a 
birth weight of 2876 g. The umbilical cord fell off natu-
rally five days later. The patient was taken to hospital 
with umbilical hemorrhage nine days after being born. 
Although cautery treatment with silver nitrate tempo-
rarily stopped the bleeding, it recurred the following 
day. Since difficulties were associated with stopping 
the umbilical hemorrhage, the patient was referred to 
our hospital 10 days after being born.
Family history
There was no history of consanguinity and no fam-
ily history of bleeding tendencies.
Symptoms at the initial diagnosis
The general condition of the patient was good, and 
his vital signs were normal; no abnormal findings were 
detected in a physical examination. Bleeding occurred 
from the umbilical stump, and it was difficult to stop 
this bleeding by compression alone (gauze with a large 
amount of blood and exudate weighed approximately 
100 g).
Laboratory findings at the hospital visit revealed 
prominent prolongations in prothrombin time (PT) 
(131.6 seconds), activated partial thromboplastin time 
(APTT) (107.9 seconds), and the hepaplastin time (HPT) 
(<10%). The cross-mixing test using plasma from the 
patient and a normal subject showed a deficiency pat-
tern, but not the inhibitor type.
A vitamin K deficiency was initially suspected due 
to the prolongations in PT and APTT; therefore, vita-
min K was administered by an intramuscular injection, 
but was not effective. Although the activities of FII, FV, 
and fibrinogen were within normal limits, plasma ac-
tivity and antigen levels of FX were <3% and 0.6%, re-
spectively. Therefore, the patient was diagnosed with 
type 1 FX deficiency. The patient’s family tree and 
their FX activities are shown in Figure 1. The admin-
istration of 20 ml/kg fresh frozen plasma (FFP) mark-
edly shortened both APTT (107.9 to 38.6 sec) and PT 
(131.6 to 17.2 sec). Since umbilical bleeding recurred, 
FFP was administered until the cessation of hemorrhag-
ing 17 days after birth.
The patient is now 2 years and 6 months old, and has 
had normal growth and developmental milestones. 
Prothrombin complex concentrate preparations were 
only administered when bleeding occurred. However, 
since multiple subcutaneous hematomas with indura-
tion developed and excessive traumatic hemorrhage of-
ten occurred, the patient was started on regular re-
placement therapy every week.
MATERIALS AND METHODS
FX activity was measured by a clotting assay using 
FX-deficient plasma. FX antigen levels were measured 
using a sandwich enzyme-linked immunosorbent as-
say (ELISA) with an A0373 anti-human FX rabbit poly-
clonal antibody (Dako, Tokyo, Japan), and was calcu-
lated from a prepared standard curve using a Dade 
Ci-Trol normal human plasma (Siemens, Munich, 
Germany).
Genomic DNA was extracted from the peripheral 
blood leukocytes of the patient and his family by stand-
ard techniques after obtaining informed consent from 
his family members. This study was approved by the 
Institutional Review Board at Kurume University 
(Research number 162). All exons and exon-intron 
boundaries of the F10 gene were amplified by the pol-
ymerase chain reaction (PCR). Primer sets were de-
signed as described by James et al. [11]. A forward and 
reverse direct sequencing analysis of all PCR products 
was performed with the Big Dye sequencing kit (PE 
Applied Biosystems, Warrington, UK) using an ABI 
Prism 310 DNA sequencer (PE Applied Biosystems). 
Mutant cDNAs were generated by site-directed mu-
tagenesis of wild-type FX cDNA inserted in pME18S-
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FL3 (Toyobo, Osaka, Japan) using the QuikChange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA). 
COS-1 cells (Riken Cell Bank, Tsukuba, Japan) were 
grown in 35-mm diameter dishes and were transiently 
transfected with 5μg of wild-type or mutant vectors 
using the lipofectamine method (Lipofectamine2000 
Transfection Reagent, Invitrogen, CA) [12].
After being incubated for 72 hours in 2 ml of se-
rum-free media, media were harvested, and cells were 
washed two times with 1×PBS and suspended in Cell 
Lysis Buffer (10x)( Cell Signaling, Beverly, MA) (10 
mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% 
Triton X-100, 1 mM sodium vanadate, and 1 mM 
N-phenylmethyl sulfonyl fluoride). One μg of protein 
was applied to 12% SDS-PAGE. A rabbit anti-human 
FX (H-120) polyclonal antibody (Santa Cruz, TX) was 
used in the Western blot analysis (ECL Prime Western 
Blotting Detection Reagent, RPN 2232) (Sigma 
Aldrich, St. Louis, Mo). The amino acid numbering of 
FX started at the initial translated methionine. The 
cDNA nucleotide number was also counted from the 
initial ATG [3]. The cited nucleotide numbers indicat-
ing the positions of the individual mutations were 
based on GenBank accession number NM_000504.3.
The alignment of amino acids around the mutated 
position and its functional effects on amino acid sub-
stitution were predicted by three types of predicting 
software: PolyPhen-2 v2.1.0r367 [13], SIFT [14] and 
MutationTaster [15].
The three-dimensional structure of the FX mutant 
protein was analyzed by the homology modeling soft-
ware MOE [16] based on the X-ray structures of 
trypsinogen and FXa (PDB 1TGT and 1G2M).
RESULTS
The patient had the inherited type 1 deficiency of 
FX (activity; <3%, antigen; 0.6%) and developed clini-
cally severe hemorrhage from the umbilical stump 9 
days after being born. The FX activities of the father 
and mother were 47% and 60%, respectively (Fig. 1). A 
family study was conducted and both parents were sus-
pected to be heterozygous for an FX deficiency.
Identification of defects in the F10 Gene
Two heterozygous mutations were identified by a 
direct sequencing analysis of all 8 exons and exon-in-
tron boundaries in the F10 gene (Fig. 2). We found a 
heterozygous missense mutation (c.730G→A, p.G244R) 
in exon 6 which had been previously reported as 
FXDebrecen from Hungary [17]. The other heterozygous 
missense mutation was c.1303G→A, p.G435S in exon 
8, which has not been reported previously.
p.G244R was detected in a heterozygous state in 
the father, but was absent in the mother. p.G435S was 
detected in a heterozygous state in the mother, but was 
Fig. 1.  The pedigree of the patient with FX deficiency
The propositus was a compound heterozygote of 
p.G244R originating from the father and p.G435S from 
the mother. Plasma FX activity levels were shown under 
each square or round box.
Fig. 2.  Genomic sequencing analysis
Leukocyte DNAs from the propositus and the parent 
were directly sequenced after the amplification of exons 
from the F10 gene by PCR. The sequencing analysis 
revealed heterozygous missense mutations in exon 6 
and exon 8.
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absent in the father (Fig. 2). We investigated the allele 
frequency of these mutations by UCSC genome brows-
er (http://genome.cse.ucsc.edu/), and found an allele 
frequency 0.01647% for c.730G→A, and no result for 
c.1303G→A.
Wild-type and mutated FX expression study
The protein expression study of wild-type or mu-
tated FX was performed by the transfection of expres-
sion vectors in which either cDNA was inserted into 
Cos-1 cells. Cells and media were harvested after 72 
hours in serum-free medium, and aliquots were applied 
to SDS-PAGE followed by Western blotting. As shown 
in Figure 3, both mutated proteins (p.G244R and p.
G435S) were expressed in the cytoplasm of transfected 
cells as well as wild-type FX; however, these were not 
secreted into media. These results suggested that these 
mutated proteins were synthesized, but could not enter 
a secretory pathway.
Amino acid alignment around G435 and structure 
analysis of p.G435S FX 
The amino acid glycine at 435 (homologous posi-
tion 211 in chymotrypsin, most common representative 
in the comparative study of the amino acid alignment 
and protein structure among trypsin-like serine proteas-
es) was completely conserved among the mammalian 
trypsin-like serine protease family (Fig. 4).
To predict the functional effects of the mutated FX 
with G435S, we used three types of mutation function 
software. This mutated FX was expected to have an 
adverse effect (damaging score, 1.000; sensitivity: 0.00; 
specificity: 1.00) by an analysis with Polymorphism 
Phenotyping version 2*. The same results were ob-
tained from the other pathogenicity software; deleteri-
ous (score: 0, median: 3.33) by SIFT, and disease-caus-
ing (p-value: 1) by MutationTaster. Similar results from 
p.G244R were also obtained with a mutation function-
al analysis by these three software applications. 
Therefore, the glycine at 435 was considered to be in-
dispensable for maintaining the structure and function 
of normal FX.
Three-dimensional structure of FX G435S
Gly 435 was located in the vicinity of the catalytic 
S1 site and within the 11th β-strand, and was buried in 
the back of the active pocket. Gly435 and Thr434 joined 
with His423 and constituted a part of the β-bulge in 
the antiparallel β-sheet. The three-dimensional protein 
model of the replacement of Gly to Ser at 435 (chymo-
trypsin number 211) was constructed using the homol-
ogy modeling software MOE (Fig. 5). When analyzed 
using a space filling model (Fig. 5B), Ser435 appeared 
to interfere with the nearby Phe403 (chymotrypsin 
number 181). This model suggested that this missense 
mutation could cause crucial structural instability and 
secretion disturbances.
Fig. 4.  Amino acid alignment around glycine 
435 of human FX
Gly435 was strictly conserved among mam-
malian trypsin-like serine proteases.
Abbreviations: hFX: human factor X, hThrom: 
human thrombin, hFVII: human factor VII, 
hFIX: human factor IX, hFXI: human factor 
XI, hFXII: human factor XII, hProC: human 
protein C, hPlasm: human plasmin, bTryp: 
bovine trypsin, bChym: bovine chymotrypsin
Fig. 3.  Western blot analysis of cell lysates and media 
after cDNA transfection into COS-1 cells
One microgram each of proteins from cell lysates and 
media was applied to SDS-PAGE. The proteins were 
transblotted to the membrane and reacted with a poly-
clonal rabbit anti-human factor X antibody.
Lanes 1 to 4 contained the proteins from cell lysates and 
lanes 5-7 from media. Lane 1 contained the proteins from 
the non-treated COS-1 cell lysate. Lanes 2 and 5 con-
tained those from COS-1 cells transfected with mutated 
cDNA (p.G244R). Lanes 3 and 6 contained those from 
mutated cDNA (p.G435S). Lane 7 contained proteins 
from COS-1 cells transfected with wild-type FX cDNA. 
Lane 8 contained those from normal human plasma. 
Mutated FX was synthesized and present in the cyto-
plasm, but was not secreted into media.
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DISCUSSION
We herein described a patient with inherited type 1 
FX deficiency who presented with severe hemorrhagic 
diathesis. A genetic analysis of F10 revealed compound 
heterozygous missense mutations. One mutation was 
previously reported, p.G244R in exon 6, while another 
was a novel p.G435S in exon 8.
The molecular analysis of the p.G244R mutation 
was described in detail by Bereczky Z, et al. from 
Hungary. They showed that the homozygous G244R 
transition caused a structural change in the FX mole-
cule and a secretion defect due to retention at the trans-
Golgi-late endosome level, subsequently leading to 
type 1 FX deficiency [17].
p.G435S FX was produced in our expression study, 
but like p.G244R FX it was non-secretable. A three-
dimensional structure analysis of this mutated FX re-
vealed a change in the fundamental structure in the 
vicinity of the S1 catalytic site. Moreover, glycine at 435 
was broadly and strictly conserved among mammalian 
trypsin-like serine proteases. These results suggested 
that p.G435S was the mutation responsible for type 1 
FX deficiency.
This patient developed a severe bleeding tendency 
soon after birth. Considering the increase in his physi-
cal activity with growth, he may need to receive regu-
lar replacements with prothrombin complex concentrate 
preparations at appropriate intervals to prevent mas-
sive bleeding and maintain his quality of life.
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